Jade Biosciences (JBIO) grants RSUs and 247,500-share option to officer

Q: Is Andrew James King’s JBIO Form 4 a stock purchase or sale?

The Form 4 shows grants , not market purchases or sales. Both the 41,250 restricted stock units and the 247,500-share stock option were acquired at $0 per derivative unit as compensation awards, classified under transaction code “A” for acquisition.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Jade Biosciences, Inc. officer Andrew James King reported equity compensation awards that increase his stake in the company. On February 12, 2026, he received 41,250 shares of common stock as a grant priced at $0 per share, bringing his directly owned common shares to 386,113.

He was also granted a stock option for 247,500 shares at an exercise price of $14.81 per share, expiring on February 11, 2036, with 247,500 derivative securities owned after the grant. The 41,250-share common stock grant is in the form of restricted stock units, vesting in four equal annual installments starting on February 15, 2026. The option vests 25% on February 15, 2027, with the remaining 75% vesting in equal monthly installments over the following three years, all subject to his continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider King Andrew James

Role See Remarks

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	247,500	$0.00	--
Grant/Award	Common Stock	41,250	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 247,500 shares (Direct); Common Stock — 386,113 shares (Direct)

Footnotes (1)

Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer. This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Form 4 Insider Transactions: What Each Field Means →

02/13/2026 - 08:00 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

King Andrew James

(Last)

(First)

(Middle)

C/O JADE BIOSCIENCES, INC.

221 CRESCENT ST., BLDG. 23, STE. 105

(Street)

WALTHAM

02453

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Jade Biosciences, Inc. [ JBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/12/2026		A		41,250⁽¹⁾	A	$0	386,113	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$14.81	02/12/2026		A		247,500		⁽²⁾	02/11/2036	Common Stock	247,500	$0	247,500	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs"). 1/4 of the total number of RSUs granted shall vest on each of the first four anniversaries of February 15, 2026, the vesting commencement date, subject to the Reporting Person's continued service through each vesting date. Each RSU represents a contingent right to receive one share of common stock of the Issuer.

2. This option represents a right to purchase shares of the Issuer's common stock, one quarter of which will vest on February 15, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

Chief Scientific Officer & Head of Research and Development

	/s/ Elizabeth Balta, as attorney-in-fact for Andrew James King	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Andrew James King report for JBIO?

Andrew James King reported equity awards, not open-market trades. He received 41,250 shares of common stock as restricted stock units and a stock option covering 247,500 shares, both granted on February 12, 2026 as part of his compensation.

How many Jade Biosciences (JBIO) shares does Andrew James King own after this Form 4?

After the reported grant, Andrew James King directly owns 386,113 shares of Jade Biosciences common stock. This total includes the 41,250 restricted stock units granted on February 12, 2026, which each represent a right to receive one share upon vesting.

What are the terms of Andrew James King’s 247,500 JBIO stock option grant?

The reported stock option covers 247,500 shares of Jade Biosciences common stock at an exercise price of $14.81 per share. It expires on February 11, 2036 and vests over four years, starting February 15, 2027, contingent on his continued service.

How do the 41,250 JBIO restricted stock units for Andrew James King vest?

The 41,250 restricted stock units vest in four equal annual installments. One quarter vests on each of the first four anniversaries of February 15, 2026, assuming Andrew James King continues serving the company through each applicable vesting date.

Is Andrew James King’s JBIO Form 4 a stock purchase or sale?

The Form 4 shows grants, not market purchases or sales. Both the 41,250 restricted stock units and the 247,500-share stock option were acquired at $0 per derivative unit as compensation awards, classified under transaction code “A” for acquisition.

What role does Andrew James King hold at Jade Biosciences (JBIO)?

Andrew James King is reported as an officer of Jade Biosciences. The remarks specify his position as Chief Scientific Officer and Head of Research and Development, linking these equity awards to his executive leadership role within the company.